Keros Therapeutics (NASDAQ:KROS) Shares Gap Down After Analyst Downgrade

Keros Therapeutics, Inc. (NASDAQ:KROS) shares gapped down prior to trading on Monday after Oppenheimer lowered their price target on the stock from $102.00 to $63.00. The stock had previously closed at $18.83, but opened at $18.25. Oppenheimer currently has an outperform rating on the stock. Keros Therapeutics shares last traded at $19.56, with a volume of 291,495 shares traded.

A number of other equities analysts have also commented on KROS. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. William Blair lowered Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Scotiabank lowered their price objective on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a research note on Friday, December 13th. Bank of America cut their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Finally, HC Wainwright decreased their price target on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $81.33.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV lifted its position in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after buying an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares during the period. Values First Advisors Inc. acquired a new stake in shares of Keros Therapeutics in the 3rd quarter valued at $89,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Keros Therapeutics in the 2nd quarter worth about $128,000. Finally, LMR Partners LLP acquired a new stake in shares of Keros Therapeutics during the 3rd quarter worth about $213,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Trading Down 7.3 %

The stock has a market capitalization of $729.13 million, a P/E ratio of -3.45 and a beta of 1.20. The firm’s fifty day moving average is $57.46 and its 200-day moving average is $52.30.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same quarter in the previous year, the business posted ($1.33) EPS. Keros Therapeutics’s revenue was up 4750.0% compared to the same quarter last year. Equities research analysts expect that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.